ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Food Hypersensitivity
Hidradenitis
Hidradenitis Suppurativa
Hypersensitivity
Pruritus

Eczema trials near New York, NY, USA:

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy (ADHAND)

The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. Th...

Enrolling
Atopic Hand Eczema
Atopic Dermatitis
Drug: Placebo
Drug: Tralokinumab

Phase 3

LEO Pharma
LEO Pharma

New York, New York, United States and 75 other locations

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

Enrolling
Atopic Dermatitis Eczema
Eczema
Drug: Placebo
Drug: IMG-007

Phase 2

Inmagene

Kew Gardens, New York, United States of America and 8 other locations

the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.OpSCF or placebo will be adm...

Active, not recruiting
Atopic Dermatitis
Biological: Placebo
Biological: OpSCF

Phase 2

Opsidio

Kew Gardens, New York, United States of America and 21 other locations

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB75...

Enrolling
Atopic Dermatitis (AD)
Biological: BFB759
Drug: Placebo

Phase 2

Bluefin Biomedicine, Inc.

Woodbury, New York, United States of America and 6 other locations

This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.

Enrolling
Eczema
Atopic Dermatitis
Drug: ATI-045
Drug: Placebo

Phase 2

Aclaris Therapeutics
Aclaris Therapeutics

New York, New York, United States and 22 other locations

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

Phase 3

AbbVie
AbbVie

New York, New York, United States and 179 other locations

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...

Enrolling
Eczema
Atopic Dermatitis
Drug: Placebo
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

East Windsor, New Jersey, United States of America and 87 other locations

This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which co...

Enrolling
Atopic Dermatitis Eczema
Atopic Dermatitis
Other: Placebo
Drug: HY209GEL Active

Phase 2

Shaperon

New York, New York, United States and 3 other locations

The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...

Active, not recruiting
Atopic Dermatitis
Drug: Dupilumab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

New York, New York, United States and 83 other locations

Locations recently updated

The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema ...

Enrolling
Atopic Dermatitis
Drug: Lebrikizumab

Phase 4

Lilly
Lilly

New York, New York, United States and 75 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems